Payment overview · 2025
General Payments
$317.79
10 reported records · 5 companies
Healthcare provider profile · identity verified
Armando J Muniz Camacho, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JUAN, PR · NPI 1912092685
Verified facts
What the public records show
CMS Open Payments records show Armando J Muniz Camacho, MD received $317.79 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 39.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Lokelma, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.96 | 39.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $116.56 | 36.7% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.08 | 12.0% | 2 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $23.21 | 7.3% | 1 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $14.98 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.79 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.30 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Puerto Rico Inc. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PBG PUERTO RICO LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 212 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 140 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1200 | 287 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1103 | 276 |
| Gabapentin | Gabapentin | 752 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 733 | 187 |
| Simvastatin | Simvastatin | 688 | 164 |
| Synthroid | Levothyroxine Sodium | 670 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 637 | 163 |
| Metoprolol Succinate | Metoprolol Succinate | 594 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 484 | 141 |
| Famotidine | Famotidine | 470 | 140 |
| Metformin Hcl | Metformin Hcl | 463 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 93 |
| Lisinopril | Lisinopril | 378 | 84 |
| Sertraline Hcl | Sertraline Hcl | 361 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 349 | 104 |
| Montelukast Sodium | Montelukast Sodium | 312 | 82 |
| Glimepiride | Glimepiride | 282 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 273 | 66 |
| Omeprazole | Omeprazole | 229 | 79 |
| Eliquis | Apixaban | 212 | 51 |
| Metformin Hcl Er | Metformin Hcl | 200 | 42 |
| Doxazosin Mesylate | Doxazosin Mesylate | 194 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 187 | 47 |
| Clonazepam | Clonazepam | 184 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 178 | 62 |
| Temazepam | Temazepam | 178 | 26 |
| Carvedilol | Carvedilol | 177 | 41 |
| Irbesartan | Irbesartan | 172 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 42 |
| Allopurinol | Allopurinol | 149 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 147 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 141 | 32 |
| Farxiga | Dapagliflozin Propanediol | 140 | 31 |
| Alprazolam | Alprazolam | 135 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 133 | 48 |
| Furosemide | Furosemide | 132 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 129 | 29 |
| Januvia | Sitagliptin Phosphate | 121 | 21 |
| Alendronate Sodium | Alendronate Sodium | 120 | 35 |
| Ramipril | Ramipril | 120 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 25 |
| Donepezil Hcl | Donepezil Hcl | 113 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 106 | 25 |
| Ezetimibe | Ezetimibe | 103 | 32 |
| Fenofibrate | Fenofibrate | 96 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 24 |
| Pregabalin | Pregabalin | 94 | 19 |
| Enalapril Maleate | Enalapril Maleate | 88 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 38 |
| Ozempic | Semaglutide | 86 | 15 |
| Xarelto | Rivaroxaban | 79 | 18 |
| Candesartan Cilexetil | Candesartan Cilexetil | 76 | 19 |
| Sucralfate | Sucralfate | 75 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 18 |
| Atenolol | Atenolol | 74 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 73 | 19 |
| Warfarin Sodium | Warfarin Sodium | 73 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 22 |
| Lansoprazole | Lansoprazole | 71 | 17 |
| Nifedipine Er | Nifedipine | 71 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 39 |
| Memantine Hcl | Memantine Hcl | 69 | 25 |
| Humalog | Insulin Lispro | 68 | 14 |
| Prednisone | Prednisone | 67 | 27 |
| Glipizide Er | Glipizide | 64 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 18 |
| Valsartan | Valsartan | 63 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 19 |
| Jardiance | Empagliflozin | 59 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 57 | 16 |
| Spironolactone | Spironolactone | 57 | 16 |
| Meloxicam | Meloxicam | 55 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 53 | 14 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 52 | 11 |
| Lorazepam | Lorazepam | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 16 |
| Nabumetone | Nabumetone | 47 | 23 |
| Diclofenac Potassium | Diclofenac Potassium | 46 | 16 |
| Folic Acid | Folic Acid | 46 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 11 |
| Azithromycin | Azithromycin | 44 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 42 | suppressed |
| Bumetanide | Bumetanide | 40 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 33 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Finasteride | Finasteride | 36 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 14 |
| Dexamethasone | Dexamethasone | 35 | 24 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 31 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 31 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 14 |
| Digoxin | Digoxin | 29 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 28 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 26 | suppressed |
| Ciclopirox | Ciclopirox | 26 | 15 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 22 |
| Potassium Citrate Er | Potassium Citrate | 23 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Galantamine Er | Galantamine Hbr | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Estazolam | Estazolam | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 12 |
| Diazepam | Diazepam | 18 | suppressed |
| Levoxyl | Levothyroxine Sodium | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.79 · 10 records | Novo Nordisk Inc | AIRSUPRA, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LOKELMA, NURTEC ODT, Ozempic, PAXLOVID | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error